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Authors’ response
We would like to thank Drs. Katsiki, Athyros 
and Karagiannis for their interest in our work [1]. 
The relationship of metabolic syndrome (MetS) 
with cardiovascular (CV) disease, dyslipidemia, hy­
pertension, glucose intolerance, insulin resistance, 
overweight, obesity and type 2 diabetes mellitus 
is well established and widely known. In any case, 
it should be pinpointed that this connection is ra­
ther obvious since the mentioned clinical entities 
are, in variable degrees of importance, part of the 
definition of the MetS or, alternatively, part of its 
predictable outcomes. It is very meritorious that 
the above mentioned authors have duly enlighte­
ned other aspects of the MetS, not necessarily 
related to the CV or endocrine systems [2]. For 
instance, MetS was found to be associated with 
increased blood lead levels [3], sex hormone bin­
ding globulin gene polymorphisms [4], augmented 
neck circumference [5] and heart rate turbulence 
[6]. Therefore, the authors’ findings are in line 
with our opinion that MetS is a multifactorial 
and polyfacetic syndrome, standing basically on 
2 tightly knotted conditions: obesity and insulin 
resistance. While obesity causes insulin resistan­
ce, on the other hand insulin resistance modifies 
adipose tissue responses to insulin and thereby 
recapitulates the obese state [1]. This situation 
may be exacerbated by other concomitant factors 
[7, 8] like abnormalities in adipokines, vitamin D 
deficiency, polycystic ovary syndrome, obstructive 
sleep apnea, hyperuricemia, renal and hepatic dise­
ases, as described by the authors [9–12] in their 
recent letter. These clinical findings are in keeping 
with current experimental research. It has been 
recently shown in animal models that insulin and 
its signaling cascade normally control cell growth, 
metabolism and survival through activation of 
mitogen­activated protein kinases (MAPKs) and 
phosphotidylinositide­3­kinase (PI3K) [13], thus 
suggesting an expanded and global influence of 
insulin on all biological systems in mammals.
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